Lang Matthew

SEC source: 0001712069-26-000007 · form4-04232026_080401.xml · derivative · entry 2

Lang Matthew · CIK 0001712069 · COO & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 223,776

Underlying: Ordinary Shares · 223,776 shares

Expires 2036-04-14

F3 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.

F4 · derivative.exercise_date: One-fourth of the shares vest on the first anniversary of April 15, 2026, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

SEC source: 0001712069-26-000007 · form4-04232026_080401.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · COO & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 184,614

F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

F2 · kind: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of April 15, 2026, subject to Reporting Person's continued service on such dates.

SEC source: 0001193125-25-280812 · ownership.xml · derivative · entry 4

Lang Matthew · CIK 0001712069 · CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 325,000 shares

Expires 2035-04-14

F3 · security: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,

F4 · security: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger.

F3 · price: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,

F4 · price: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger.

F7 · derivative.exercise_date: This option was granted on April 15, 2025. The option provided for vesting as to 25% of the shares initially subject to the option on the first anniversary of April 14, 2025, and as to 1/48th of the shares initially subject to the option on each monthly anniversary thereafter.

SEC source: 0001193125-25-280812 · ownership.xml · derivative · entry 3

Lang Matthew · CIK 0001712069 · CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 46,875 shares

Expires 2035-05-19

F3 · security: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,

F4 · security: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger.

F3 · price: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,

F4 · price: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger.

F6 · derivative.exercise_date: This option provided for vesting in 48 substantially equal monthly installments from May 20, 2025.

SEC source: 0001193125-25-280812 · ownership.xml · derivative · entry 2

Lang Matthew · CIK 0001712069 · CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires not disclosed

F5 · price: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the RSUs.

F5 · derivative.exercise_date: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the RSUs.

F5 · derivative.expiration_date: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the RSUs.

SEC source: 0001193125-25-280812 · ownership.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus

F2 · kind: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").

F1 · price: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus

F2 · price: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").

F5 · price: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the RSUs.

SEC source: 0000950170-25-076571 · ownership.xml · derivative · entry 1

Lang Matthew · CIK 0001712069 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,875

Underlying: Common Stock · 46,875 shares

Expires 2035-05-19

F1 · derivative.exercise_date: The options will vest and become exercisable in 48 substantially equal monthly installments after the date of grant, such that the option will be vested in full on the fourth anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.

SEC source: 0001415889-25-005775 · form4-02272025_120200.xml · derivative · entry 3

Lang Matthew · CIK 0001712069 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,250

Underlying: Common Stock · 56,250 shares

Expires 2035-02-09

F3 · derivative.exercise_date: The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria.

SEC source: 0001415889-25-005775 · form4-02272025_120200.xml · derivative · entry 2

Lang Matthew · CIK 0001712069 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 450,000

Underlying: Common Stock · 450,000 shares

Expires 2035-02-09

F2 · derivative.exercise_date: 12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.

SEC source: 0001415889-25-005775 · form4-02272025_120200.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,500

F1 · kind: 12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date.

SEC source: 0001209191-24-003276 · doc4.xml · derivative · entry 2

Lang Matthew · CIK 0001712069 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2034-02-08

F2 · derivative.exercise_date: 12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months.

SEC source: 0001209191-24-003276 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

F1 · date: The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001209191-23-045439 · doc4.xml · derivative · entry 1

Lang Matthew · CIK 0001712069 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,250,000

Underlying: Common Stock · 2,250,000 shares

Expires 2033-08-09

F1 · derivative.exercise_date: 1/4 of the option shares shall vest on July 1, 2024, with the remaining option shares to vest in equal monthly installments over the following thirty-six months.

SEC source: 0001209191-23-017719 · doc4.xml · derivative · entry 8

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 111,111 shares

Expires not disclosed

F8 · derivative.exercise_price: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time.

F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").

F8 · price: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time.

F8 · derivative.exercise_date: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time.

F8 · derivative.expiration_date: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time.

SEC source: 0001209191-23-017719 · doc4.xml · derivative · entry 7

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 90,310 shares

Expires 2031-04-14

F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").

F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and the holder thereof was entitled to the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable-exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.

F7 · derivative.exercise_date: One-fourth of the options vested on April 15, 2022, and one-sixteenth of the options vest each quarter thereafter.

SEC source: 0001209191-23-017719 · doc4.xml · derivative · entry 6

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 170,396 shares

Expires 2030-04-02

F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").

F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and the holder thereof was entitled to the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable-exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.

F6 · derivative.exercise_date: One-fourth of the options vested on April 3, 2021, and one-sixteenth of the options vest each quarter thereafter.

SEC source: 0001209191-23-017719 · doc4.xml · derivative · entry 5

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 152,110 shares

Expires 2029-04-04

F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").

F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and the holder thereof was entitled to the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable-exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.

F4 · derivative.exercise_date: These options are fully vested.

SEC source: 0001209191-23-017719 · doc4.xml · derivative · entry 4

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 87,050 shares

Expires 2028-04-15

F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").

F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and the holder thereof was entitled to the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable-exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.

F4 · derivative.exercise_date: These options are fully vested.

SEC source: 0001209191-23-017719 · doc4.xml · derivative · entry 3

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 220,000 shares

Expires 2027-07-16

F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").

F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and the holder thereof was entitled to the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable-exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.

F4 · derivative.exercise_date: These options are fully vested.

SEC source: 0001209191-23-017719 · doc4.xml · nonDerivative · entry 2

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").

F3 · price: Reflects restricted stock units ("RSUs"). Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time.

SEC source: 0001209191-23-017719 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 241,158

F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").

F2 · price: At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration").

SEC source: 0001209191-23-004285 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 354,303

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

SEC source: 0001209191-23-001951 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 355,575

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

SEC source: 0001209191-22-054195 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 358,354

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

SEC source: 0001209191-22-052984 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 360,287

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

SEC source: 0001209191-22-046001 · doc4.xml · nonDerivative · entry 2

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 363,966

F3 · shares: The common shares are sold by the Reporting Person to cover the tax obligation realized upon the vesting of common shares underlying the PSUs reported in Table I.

F4 · price: The shares were sold at prices ranging from $18.22 to $18.23. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-046001 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 395,180

F1 · shares: The common shares are acquired or to be acquired upon the vesting of performance-based restricted stock units ("PSUs") granted to the Reporting Person on April 3, 2020. The PSUs were granted under the Issuer's 2016 Equity Incentive Plan and vest as follows: (i) 62,390 common shares underlying the PSUs vest upon the latter to occur of (a) the certification (the "Certification") by the Compensation Committee of the achievement of all of the performance milestones set forth in the applicable award agreement and (b) April 3, 2022, and (ii) 62,390 common shares underlying the PSUs vest upon the latter to occur of (a) the Certification by the Compensation Committee and (b) April 3, 2023, in each case, subject to the Reporting Person's continuous service to the Issuer or its affiliates on each such vesting date.

F2 · shares: On August 12, 2022, the Compensation Committee certified the achievement of all of the performance milestones, resulting in the immediate vesting of 62,390 common shares underlying the PSUs. The remaining 62,390 common shares underlying the PSUs will vest on April 3, 2023, subject to the Reporting Person's continuous service to the Issuer or its affiliates on that date.

SEC source: 0001209191-22-042694 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,400

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

SEC source: 0001209191-22-041615 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,335

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

F2 · price: The shares were sold at prices ranging from $13.40 to $13.48. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-025174 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 276,037

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

F2 · price: The shares were sold at prices ranging from $10.45 to $10.46. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-024786 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 284,039

F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 15, 2023, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.

SEC source: 0001209191-22-023666 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,928

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

F2 · price: The shares were sold at prices ranging from $13.78 to $13.86. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-002202 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,364

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

SEC source: 0001209191-21-059910 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,839

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

SEC source: 0001209191-21-046492 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 186,510

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

SEC source: 0001209191-21-027285 · doc4.xml · derivative · entry 2

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,310

Underlying: Common Shares · 90,310 shares

Expires 2031-04-14

F2 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 15, 2022, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.

SEC source: 0001209191-21-027285 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 193,464

F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 15, 2022, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.

SEC source: 0001209191-21-026086 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,003

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

F2 · price: The shares were sold at prices ranging from $18.60 to $19.00. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-021304 · doc4.xml · derivative · entry 3

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 220,000

Underlying: Common Shares · 30,000 shares

Expires 2027-07-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Fully vested.

SEC source: 0001209191-21-021304 · doc4.xml · nonDerivative · entry 2

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,865

F1 · shares: Shares sold pursuant to a 10b5-1 trading plan.

F2 · price: The shares were sold at prices ranging from $25.05 to $25.28. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-021304 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,865

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-064824 · doc4.xml · derivative · entry 4

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Shares · 10,000 shares

Expires 2027-07-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

SEC source: 0001209191-20-064824 · doc4.xml · nonDerivative · entry 3

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,865

F1 · shares: Shares sold pursuant to a 10b5-1 trading plan.

F3 · price: The shares were sold at prices ranging from $26.14 to $26.43. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-064824 · doc4.xml · nonDerivative · entry 2

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,165

F1 · shares: Shares sold pursuant to a 10b5-1 trading plan.

F2 · price: The shares were sold at prices ranging from $25.065 to $25.99. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-064824 · doc4.xml · nonDerivative · entry 1

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,865

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-062937 · doc4.xml · derivative · entry 6

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,000

Underlying: Common Shares · 19,400 shares

Expires 2027-07-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

SEC source: 0001209191-20-062937 · doc4.xml · nonDerivative · entry 4

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,865

F1 · shares: Shares sold pursuant to a 10b5-1 trading plan.

F3 · price: The shares were sold at prices ranging from $25.05 to $25.48. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-062937 · doc4.xml · nonDerivative · entry 3

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,265

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-062937 · doc4.xml · derivative · entry 5

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 279,400

Underlying: Common Shares · 600 shares

Expires 2027-07-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

SEC source: 0001209191-20-062937 · doc4.xml · nonDerivative · entry 2

Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,865

F1 · shares: Shares sold pursuant to a 10b5-1 trading plan.

F2 · price: The shares were sold at prices ranging from $25.07 to $25.09. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.